Insider Trading Roundup: RXi Pharmaceuticals Corporation $RXII

9591645d5db6965a33bff4261d5e21e2

RXi Pharmaceuticals Corporation (RXII) insider have most recently took part in a trading activity. On Aug 24, 2017 Cauwenbergh Geert, President & CEO bought 10,000 shares having total worth of $5,500 at the price of $0.55 per share, following the transaction a total of 137,533 shares owned by Cauwenbergh Geert. Before this latest buy, Cauwenbergh Geert purchased RXII at 7 other times during the past twelve months, for a total investment of $48,200 at an average of $0.69 per share.

The stock has experienced a total of 2 insider trades in the past three months. These trades include 2 buy trades. Furthermore, over the past 12 months , the stock was traded 8 times by insiders. an employee of the company was the buyer in 8 instances.

Time Frame Number of Insider Buy Number of Insider Sell Stock Price Change(%)
3 Month 2 0 -27.22%
12 Month 8 0 -81.25%

Shares of RXi Pharmaceuticals Corporation (RXII) traded down 2.7% on Aug 23, 2017, hitting $0.54. 129,231 shares of the company’s stock traded hands. RXi Pharmaceuticals Corporation has a 52 week low of $0.54 and a 52 week high of $2.95. The company’s market cap is $13 million.

RXi Pharmaceuticals Corporation (RXII) last announced its earnings results on Aug 10, 2017. The company reported -0.11 earnings per share (EPS) for the quarter. During the same quarter in the previous year, the company posted -0.34 earnings per share. The company’s revenue for the quarter was down 100% on a year-over-year basis.

2017-08-10 2017-05-11 2017-03-30 2016-11-10 2016-08-11 2016-05-12 2016-03-30 2015-11-12 2015-08-12 2015-05-13
earnings per share -0.11 -0.12 -0.60 -0.34 -0.34 -0.34 -0.04 -0.04 -0.05 -0.13
Revenue(M) 0 0 0 0 0.01 0.01 0 0 0 0.03

RXi Pharmaceuticals Corp was incorporated in Delaware as a wholly owned subsidiary of Galena on September 8, 2011 in preparation for its planned spin-off from Galena, which was completed on April 27, 2012. The Company is a biotechnology company. Its main business activities are discovering, developing and commercializing therapies based on its proprietary, new-generation RNA interference platform. Its proprietary therapeutic platform is comprised of novel RNAi compounds, referred to as rxRNA compounds. It has developed a number of unique forms of rxRNA compounds, all of which have been shown to be potent both in vitro and in preclinical in vivo models. These RNAi compounds include rxRNAori and sd-rxRNA, or ‘self-delivering’ RNA. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specific waste products. It is also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of bio-hazardous materials.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.